The French Market GEO Gap: Why Non-English Pharma Is Flying Blind in AI Search
If your drug is marketed in France, AI essentially does not see it.
That is not speculation. It is the first quantified finding from cross-language pharma GEO benchmarking ever conducted. While English-language pharmaceutical brands generate dozens of AI Overview results, trigger rich citations, and benefit from deep source ecosystems, French-language pharma queries return zero Google AI Overviews. Not a few. Not a trickle. Zero.
For an industry that invests billions in European market access, this represents a visibility crisis that almost nobody is measuring, and even fewer are addressing. This article presents the first public data on the multilingual GEO pharma Europe gap and lays out a concrete strategy for closing it.
Data source: PharmaGEO platform analysis across OpenAI, Gemini, and Perplexity (2025)
The AI Overviews Desert: Zero in French, Dozens in English
Google AI Overviews (AIO) have become one of the most prominent features in health-related search. When a patient or HCP searches for a drug in English, Google increasingly generates an AI-synthesized answer at the top of the results page, pulling from authoritative sources and reshaping how users interact with pharmaceutical information.
But that experience does not translate across languages.
AI Overview Generation by Language
| Query Category | English AI Overviews | French AI Overviews |
|---|---|---|
| Entyvio | 67 | 0 |
| Psoriasis treatments | 50 | 0 |
| Beyfortus | 15 | 0 |
| All other French-language products | N/A | 0 |
The pattern is absolute. Across every French-language pharmaceutical query in the dataset, Google generated zero AI Overviews. Not low numbers. Not inconsistent triggering. A complete absence.
Key Takeaway: Google AI Overviews appear to be primarily an English-language phenomenon in pharma. If your GEO pharma Europe strategy assumes uniform AI behavior across languages, your data is fundamentally misleading.
This means that French patients searching for medication information, French physicians looking up treatment protocols, and French pharmacists checking drug interactions are operating in a completely different AI search environment than their English-speaking counterparts. They see traditional blue links. They do not see AI-synthesized answers. And the sources that inform those non-existent overviews are never surfaced.
For pharma brands with significant French market revenue, this is not a technical footnote. It is a strategic blind spot.
The Score Gap: Same Drug, Two Languages
To understand the real-world impact of the multilingual AI search gap, consider a controlled comparison: the same drug, queried in two languages.
Dupixent (dupilumab), manufactured by Sanofi and Regeneron, is one of the most commercially significant drugs marketed in both English- and French-speaking markets. It treats atopic dermatitis, asthma, and other inflammatory conditions. It is a genuinely global brand, making it the ideal case study for GEO pharma Europe performance.
Dupixent: English vs. French GEO Performance
| Metric | Dupixent (EN) | Dupixent (FR) | Gap |
|---|---|---|---|
| GEO Score | 61 | 59 | -2 points |
| Reliability | 84% | 78% | -6 points |
| AI Overviews | Multiple | 0 | Total absence |
At first glance, a two-point score difference seems minor. But the underlying dynamics reveal a much deeper problem.
The reliability gap is the real story. Dupixent EN achieves 84% reliability, meaning AI engines consistently return accurate, well-sourced information. Dupixent FR drops to 78%. That six-point decline reflects fewer authoritative French-language sources available for AI models to draw from, less structured data in French medical databases, and a thinner ecosystem of machine-readable French pharmaceutical content.
When AI models lack high-quality French-language sources, they do one of three things: they fall back to English sources (creating language mismatch), they generate less confident answers, or they decline to generate answers at all. In the French market, the third option dominates.
Key Takeaway: The same molecule, same manufacturer, same clinical data, yet a measurably worse AI experience in French. The gap is not about the drug. It is about the language ecosystem surrounding it.
This finding has direct implications for every pharma company operating across European markets. If Dupixent, backed by Sanofi's considerable resources and a strong French market presence, still shows a measurable GEO gap, smaller brands with less market investment face even steeper challenges.
Related: How Top Pharma Brands Score in GEO Benchmarking
French-Market Brand Performance: The Full Picture
Dupixent is not an outlier. The PharmaGEO dataset includes seven French-market pharmaceutical brands, spanning oncology, immunology, dermatology, and consumer health. The results paint a consistent picture of lower performance and limited AI visibility for non-English AI search optimization.
French-Market Brand GEO Scores
| Brand | Therapeutic Area | GEO Score | Reliability | Visibility |
|---|---|---|---|---|
| Dupixent FR | Immunology / Dermatology | 59 | 78% | 70% |
| Yescarta | Oncology (CAR-T) | 57 | 81% | — |
| Imfinzi | Oncology | 54 | 77% | 79% |
| Ontozry | Neurology (Epilepsy) | 50 | 80% | — |
| Ledaga | Oncology (Dermatological) | 49 | 81% | 89% |
| Wegovy | Obesity / Metabolic | 47 | 77% | — |
| Voltaren | Consumer Health / Pain | 43 | 74% | — |
Average French-market GEO Score: 51.3
Several patterns emerge from this data.
Reliability clusters between 74% and 81%. No French-market brand achieves the 84%+ reliability scores seen in top-performing English-language brands. The ceiling is lower, and the floor is lower, reflecting the systemic nature of the French pharmaceutical AI visibility problem rather than individual brand failures.
Consumer brands suffer most. Voltaren, a well-known OTC pain relief brand, scores just 43 with 74% reliability. Consumer health queries in French generate the weakest AI performance, likely because the mix of consumer health sites, forums, and commercial content in French is less structured and less authoritative than the medical literature that supports prescription brands.
Visibility scores vary significantly. Where measured, visibility ranges from 70% (Dupixent FR) to 89% (Ledaga). This suggests that some French-market brands are being mentioned by AI engines when they do generate responses, but the frequency and depth of those responses remain limited by the overall French-language source ecosystem.
Key Takeaway: The French-market GEO average of 51.3 sits well below the English-language benchmarks. This is not a brand-level problem. It is a systemic, language-level deficit in multilingual pharma AI optimization.
Related: What Makes a Good GEO Score in Pharma
The Vidal.fr Dependency: One Source Rules French Pharma AI
In the English-language pharma GEO ecosystem, AI models draw from a diverse array of sources: FDA labels, PubMed, Mayo Clinic, WebMD, Cleveland Clinic, manufacturer sites, and YouTube. That diversity creates redundancy, cross-validation, and resilience. If one source is unavailable or incomplete, others fill the gap.
In French, the ecosystem is dramatically narrower. One source dominates: Vidal.fr.
French Pharma AI Source Hierarchy
| Source | Role | Reliability |
|---|---|---|
| Vidal.fr | Primary drug reference | 90% |
| EMA (ema.europa.eu) | Regulatory / Label data | High |
| ANSM | French national drug agency | Moderate |
| French medical literature | Clinical evidence | Low AI accessibility |
| YouTube (French) | Patient education | Minimal presence |
Vidal.fr functions as the French equivalent of FDA drug labels combined with a clinical reference database. It is the source that French HCPs, pharmacists, and informed patients turn to for drug information. And in the AI search ecosystem, it has become the single most reliable French-language pharma source, achieving 90% reliability when cited by AI engines.
This dominance is both a strength and a vulnerability.
The strength is clear: when AI models cite Vidal.fr, the information is accurate and authoritative. Brands that are well-represented on Vidal.fr benefit from that authority.
The vulnerability is equally clear: French pharma AI visibility depends disproportionately on a single source. If Vidal.fr content is not optimized for machine readability, if a brand's Vidal.fr listing is incomplete, or if AI models cannot effectively parse Vidal.fr's structure, the entire French-language AI presence for that brand suffers.
By contrast, the European Medicines Agency (EMA) serves as a secondary source, providing regulatory documents and European Public Assessment Reports (EPARs) in multiple languages. ANSM, the French national medicines agency, appears in some AI responses but lacks the structured, machine-readable format that AI models prefer.
French medical literature is the most significant gap. While PubMed indexes French-language studies, the volume is a fraction of English-language publications. AI models trained predominantly on English-language corpora have limited access to French clinical evidence, creating a feedback loop where French pharmaceutical AI visibility remains low because the training data is thin.
YouTube in French is nearly absent from pharma AI citations. English-language pharma queries frequently trigger YouTube citations for patient education content and mechanism-of-action videos. French-language equivalents either do not exist at the same scale or are not structured for AI discovery.
Key Takeaway: The French pharma AI source ecosystem is dangerously concentrated. Vidal.fr at 90% reliability is an asset, but single-source dependency creates fragility that no English-language brand would accept.
Why the Gap Exists: Structural Causes of the Multilingual AI Deficit
The French-market GEO gap is not an accident. It is the predictable result of several compounding structural factors that affect all non-English pharmaceutical markets.
1. AI Training Data Bias
Large language models are trained on corpora that are overwhelmingly English. Estimates suggest that English represents 50-60% of major AI training datasets, while French represents approximately 4-5%. This asymmetry means AI models have far more context, nuance, and source material for English-language pharmaceutical queries. They can cross-reference, validate, and synthesize English sources with a depth that is simply unavailable in French.
2. English-Language Scientific Publishing Dominance
An estimated 95%+ of indexed medical literature is published in English. Even French researchers at French institutions publish primarily in English to reach global audiences. This means the clinical evidence base that AI models rely on is almost entirely English, creating a structural disadvantage for any non-English query that requires clinical data.
3. Structured Data Availability
English-language pharmaceutical information benefits from decades of structured data investment. FDA labels follow standardized formats. ClinicalTrials.gov provides machine-readable trial data. DailyMed offers structured product labeling. French equivalents exist but are less standardized, less machine-readable, and less extensively indexed by AI systems.
4. Google's AI Overview Deployment Strategy
Google appears to have deployed AI Overviews for health queries primarily in English-language markets first. Whether this reflects technical readiness, regulatory caution in European markets, or strategic prioritization, the result is a binary divide: English queries get AI Overviews, French queries do not.
5. Content Investment Asymmetry
Pharmaceutical companies invest disproportionately in English-language digital content. US and UK market websites are typically more detailed, better structured, and more frequently updated than their French equivalents. This creates a quality gap that AI models detect and reflect in their outputs.
Key Takeaway: The multilingual GEO gap is structural, not incidental. It will not self-correct. Closing it requires deliberate investment in non-English AI search optimization.
Implications for European Pharma: Beyond France
While this analysis focuses on French-language data, the implications extend across every non-English European market. If the gap exists for French, the second most common language in pharmaceutical regulation, it almost certainly exists for German, Spanish, Italian, Portuguese, Dutch, and Nordic languages.
Consider the scale of the problem:
- Germany, the largest pharmaceutical market in Europe, likely faces similar AI Overview gaps for German-language queries.
- Spain and Italy, with significant pharmaceutical industries and patient populations, are probably operating in the same AI visibility deficit.
- Nordic markets, despite high English proficiency, still have patients and HCPs who search in their native languages.
The EU's regulatory framework, with EMA providing centralized authorization and national agencies handling local implementation, creates an opportunity for coordinated action. But today, no standardized approach exists for multilingual pharma AI optimization across European markets.
For pharma companies with pan-European portfolios, this means that GEO strategies developed for the US or UK market are not transferable. A brand that scores well in English may be virtually invisible in every other European language. Without language-specific benchmarking, companies are, quite literally, flying blind.
Related: Building a Pharma GEO Strategy From Scratch
The Non-English GEO Strategy: Eight Recommendations for European Pharma
Closing the multilingual pharma AI optimization gap requires deliberate, sustained action across content, technical infrastructure, and measurement. The following recommendations are specific to the French market but applicable, with adaptation, to any non-English European market.
1. Optimize French-Language Owned Content for GEO
Your French-language brand site, patient portals, and HCP resources need to be written and structured for AI consumption, not just human reading. This means clear heading hierarchies, direct question-and-answer formats, concise paragraph structures, and explicit entity definitions. AI models extract information differently than humans browse, so your French content must be optimized for both.
2. Ensure EMA Product Pages Are Machine-Readable
European Public Assessment Reports (EPARs) and product information pages on ema.europa.eu are available in all EU languages. Work with regulatory affairs to ensure these pages contain structured data markup, clean HTML, and are accessible to AI crawlers. EMA content carries inherent authority, but only if AI models can parse it effectively.
3. Create French-Language FAQ Content
FAQ pages are among the most effective content formats for GEO because they mirror how users query AI engines. Develop comprehensive FAQ content in French covering indications, dosing, side effects, drug interactions, and patient eligibility. Implement FAQPage schema markup on every FAQ page.
4. Leverage the Vidal.fr Integration
Given Vidal.fr's dominance (90% reliability) in French pharma AI, ensure your brand's Vidal.fr presence is complete, accurate, and current. Treat Vidal.fr as a primary channel for French pharmaceutical AI visibility, not just a regulatory listing. Investigate whether enhanced content partnerships with Vidal.fr are possible within regulatory guidelines.
5. Build French-Language Medical Literature Presence
Support the publication of French-language clinical summaries, review articles, and practice guidelines. While primary research will continue to be published in English, French-language secondary literature, particularly evidence summaries and treatment guidelines endorsed by French medical societies, can significantly enrich the AI source ecosystem.
6. Implement Multilingual Structured Data
Deploy schema.org markup in French on all brand-owned properties. This includes MedicalCondition, Drug, MedicalWebPage, and FAQPage schemas with French-language values. Structured data provides AI models with explicit, machine-readable signals that reduce reliance on natural language parsing, where non-English content is at a disadvantage.
7. Create YouTube Content in French
The near-total absence of French-language pharma content in AI citations represents an opportunity. Develop mechanism-of-action videos, patient education content, and HCP resources in French on YouTube. Optimize titles, descriptions, and transcripts for French-language pharmaceutical queries. YouTube citations are a growing factor in English-language pharma GEO, and the French market is wide open.
8. Monitor AI Performance by Language
Implement language-specific GEO tracking. Measure GEO scores, reliability, visibility, and source citations separately for each language market. Without language-level benchmarking, you cannot identify gaps, track progress, or justify investment. GEO pharma Europe strategies must be measured in every language they target.
Key Takeaway: Non-English GEO is not a variation on English GEO. It requires a dedicated strategy, dedicated content, and dedicated measurement. The brands that move first will capture a structural advantage in markets where competition for AI visibility is currently near zero.
Related: Source Authority and Why It Matters for Pharma GEO
Frequently Asked Questions
Why do French pharma queries generate zero Google AI Overviews?
Google AI Overviews for health-related queries appear to be deployed primarily in English-language markets as of 2025. This likely reflects a combination of factors: the maturity of English-language health content, Google's phased rollout strategy across languages, and potentially greater regulatory caution in European markets. The result is that French-language pharmaceutical queries receive no AI-synthesized answers, leaving users with traditional search results only.
How does the GEO score gap between English and French affect patient outcomes?
While the direct impact on patient outcomes requires further study, the GEO gap means that French-speaking patients receive a fundamentally different AI search experience than English-speaking patients. They see fewer synthesized answers, encounter less curated source citations, and have less AI-assisted guidance when researching medications. This information asymmetry could contribute to differences in health literacy and treatment awareness across language markets.
Is Vidal.fr's dominance in French pharma AI a problem?
It is both an asset and a risk. Vidal.fr's 90% reliability means that when AI models cite it, the information is highly accurate. However, single-source dependency creates fragility. If Vidal.fr's content structure changes, if AI models alter how they parse the site, or if a brand's Vidal.fr listing is incomplete, the entire French AI presence for that brand is compromised. Diversifying the French pharma source ecosystem is a strategic priority.
Do other European languages face the same GEO gap as French?
Almost certainly, yes. French is one of the most widely used languages in European pharmaceutical regulation, and it still shows a significant GEO gap. German, Spanish, Italian, and other European languages likely face equal or greater deficits, particularly in smaller markets with less digital pharmaceutical content. Any brand with a pan-European portfolio should assume that non-English GEO performance is lower until measured otherwise.
What is the fastest way to improve French-market GEO scores?
The highest-impact immediate actions are: (1) optimize French-language owned content with clear Q&A structures and schema markup, (2) ensure your Vidal.fr listing is complete and current, and (3) create French-language FAQ pages with FAQPage schema. These three steps address the most common AI source gaps and can show measurable improvements within one to two quarters. Longer-term strategies like French YouTube content and medical literature investment take more time but build a more resilient presence.
How should pharma companies measure multilingual GEO performance?
Implement language-specific tracking that measures GEO scores, reliability, visibility, and source citations independently for each language market. Do not average scores across languages, as this masks critical gaps. Benchmark against language-specific competitors and track AI Overview availability by market. Tools like the PharmaGEO platform provide cross-language benchmarking specifically designed for pharmaceutical brands operating across multiple European markets.
Conclusion: The First-Mover Advantage in Non-English GEO
The data is unambiguous. French-language pharmaceutical queries exist in an AI visibility vacuum. Zero AI Overviews. Lower reliability. A source ecosystem dominated by a single reference. And an industry that has not yet recognized the problem, let alone begun solving it.
This is precisely why the opportunity is so significant.
Every pharma company with French-market products is operating with the same deficit. None have optimized for multilingual pharma AI optimization because none have had the data to quantify the gap. That changes now.
The brands that act first, by building French-language GEO content, diversifying beyond Vidal.fr dependency, investing in French YouTube and medical literature, and implementing language-specific measurement, will capture a structural advantage in a market where AI competition is currently nonexistent.
The GEO pharma Europe gap will not remain indefinitely. Google will eventually expand AI Overviews to French and other European languages. AI models will gradually improve their non-English pharmaceutical knowledge. When that happens, the brands with established, authoritative, machine-readable French content will be the ones AI engines cite.
The question is not whether non-English pharma GEO matters. The data already answers that. The question is whether your brand will be visible when AI search finally arrives in your market, or whether you will still be flying blind.
Data source: PharmaGEO platform analysis across OpenAI, Gemini, and Perplexity (2025). This article represents the first published cross-language GEO benchmarking data for the pharmaceutical industry.
See the full benchmark methodology | Explore all PharmaGEO articles
See how your brand appears in AI answers.
Get a cross-LLM reputation report in minutes. No patient data. EU-based storage.
Data source: PharmaGEO platform analysis of 23 pharmaceutical brands across OpenAI, Gemini, and Perplexity (2025)